This suggests that treatment with MR inhibitors might reverse the adverse cardiovascular effects of SAME (which include hypokalemia, hypertension, proteinuria and end-organ damage), while promoting the beneficial metabolic effects of Hsd11b2 inactivation (Mullins et al., 2015). The gene discussed is HSD11B2; the disease is Hypokalemia.